Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) unit Shandong Zibo Xincat Pharmaceutical recently obtained approval of azithromycin for suspension from China's National Medical Products Administration after it passed the regulator's quality and efficacy consistency evaluation, a Tuesday bourse filing said.
Azithromycin is a macrolide antibiotic suitable for the treatment of mild-to-moderate infections caused by certain designated microbial sensitive strains, according to the pharmaceuticals and chemical products company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。